Ibandronate Eg

Active Ingredient:: Ibandronic Acid Monosodium Salt, Monohydrate
Origin:: EU

Ibandronate Eg (Ibandronic Acid Monosodium Salt, Monohydrate)

Q: What is Ibandronate Eg used for?

Ibandronate Eg is a prescription‑only bisphosphonate indicated for the treatment of osteoporosis in postmenopausal women and for preventing skeletal‑related events such as pathological fractures in patients with bone metastases.

Q: How does Ibandronic Acid work in the body?

Ibandronic Acid binds to bone mineral surfaces and, when osteoclasts attach, it is taken up into the cells where it blocks farnesyl pyrophosphate synthase in the mevalonate pathway. This inhibition leads to osteoclast apoptosis, reducing bone resorption and helping maintain bone strength.

Q: What is the usual dose of Ibandronate Eg?

The dosing regimen for Ibandronate Eg is determined by the prescribing clinician based on the patient’s condition, renal function, and treatment goals. Only a qualified healthcare professional should set the dose and administration schedule.

Q: Is Ibandronate Eg safe during pregnancy or breastfeeding?

Safety data for Ibandronate Eg in pregnancy and lactation are limited. It is generally contraindicated unless the potential benefit justifies the potential risk to the fetus or infant, and it should only be used under close medical supervision.

Q: How do I order Ibandronate Eg from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Q: How does Ibandronate compare with other bisphosphonates?

Ibandronate is similar to other bisphosphonates such as alendronate and zoledronic acid in its antiresorptive mechanism, but it is administered intravenously and has a longer dosing interval, which can improve patient convenience compared with more frequent oral regimens.

Q: What are the storage and handling requirements for Ibandronate Eg?

Ibandronate Eg should be stored at ambient temperature, below 25 °C, protected from light and moisture, and kept in its original packaging until ready for use. Do not freeze the solution.

Q: How is Ibandronate Eg given to patients?

The product is supplied as an intravenous solution that is administered by a qualified healthcare professional through a controlled IV infusion. The infusion rate and duration are determined by the prescriber and nursing staff according to clinical guidelines.

Q: What are the most serious risks associated with Ibandronate Eg?

Serious risks include osteonecrosis of the jaw, atypical femoral fractures, and severe renal impairment. Patients should be monitored for signs of jaw pain, unusual thigh or groin pain, and changes in kidney function during treatment.

Q: Who should not use Ibandronate Eg?

Ibandronate Eg is contraindicated in patients with severe renal impairment (eGFR <30 mL/min), known hypersensitivity to ibandronate or any formulation components, and in individuals with active dental infections or recent invasive dental procedures unless the benefits outweigh the risks.

Ibandronic Acid Monosodium Salt, Monohydrate, the active ingredient in Ibandronate Eg, is a bisphosphonate presented as an intravenous solution for intravenous use. It treats osteoporosis in postmenopausal women and helps prevent skeletal‑related events in patients with bone metastases. It is indicated for long‑term management of bone density loss and for reducing fracture risk associated with metastatic disease.

GNH India supplies Ibandronate Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, providing reliable sourcing and regulatory support for clinical use.

Manufacturer / TM Owner

Eurogenerics N.V./S.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ibandronate Eg is a bisphosphonate that acts on bone remodeling pathways to decrease bone resorption and strengthen skeletal integrity.

Osteoporosis in postmenopausal women: reduces risk of vertebral, hip and other fractures by increasing bone mineral density.
Bone metastases (skeletal‑related events): lowers incidence of pathological fractures, spinal cord compression and need for radiation or surgery.
Paget’s disease of bone: helps normalize accelerated bone turnover and improve bone pain.

How It Works

Ibandronate binds avidly to hydroxyapatite crystals on bone surfaces, especially at sites of active remodeling. When osteoclasts attach to the drug‑coated bone, ibandronate is internalized and inhibits farnesyl pyrophosphate synthase within the mevalonate pathway, preventing prenylation of small G‑proteins. This disruption induces osteoclast apoptosis, thereby reducing bone resorption and allowing osteoblast‑mediated bone formation to predominate.

Side Effects

Ibandronate may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

Acute phase reaction: fever, myalgia, arthralgia, and flu‑like symptoms shortly after infusion.
Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.
Transient hypocalcemia: low serum calcium levels that usually resolve with supplementation.
Musculoskeletal pain: bone or joint aches occurring days to weeks after administration.

Serious or Rare Side Effects

Osteonecrosis of the jaw (ONJ): exposed bone in the maxillofacial region, often after dental procedures.
Atypical femoral fractures: subtrochanteric or diaphyseal fractures with minimal trauma.
Severe renal impairment: acute kidney injury or worsening of pre‑existing renal disease.

Precautions & Warnings

Before initiating Ibandronate therapy, clinicians should evaluate patient risk factors and follow specific safety measures.

Renal function: assess creatinine clearance; avoid use in severe renal impairment (eGFR <30 mL/min).
Calcium and vitamin D status: ensure adequate supplementation to prevent hypocalcemia.
Dental health: perform dental examination and treat existing oral disease before treatment.
Concomitant medications: review use of other antiresorptives or nephrotoxic drugs.
Pregnancy and lactation: contraindicated unless benefits outweigh risks; limited data available.
Store at ambient temperature: keep below 25 °C, protect from light and moisture, and retain in original packaging until use.

Avoid Interactions

Ibandronate can interact with several medicines, altering its safety or efficacy.

Major Interactions (Avoid)

Concurrent use of other bisphosphonates or potent antiresorptives: may increase risk of oversuppression of bone turnover.
High-dose NSAIDs or aminoglycosides: can exacerbate renal toxicity.

Moderate Interactions (Monitor Closely)

Calcium, magnesium, or aluminum‑containing antacids: reduce oral absorption (not applicable to IV but may affect timing of other IV drugs).
Loop diuretics: may potentiate hypocalcemia.
Corticosteroids: may increase risk of osteonecrosis of the jaw.
Warfarin: monitor INR as bisphosphonates may affect coagulation parameters.

Frequently Asked Questions

Ibandronate Eg is a prescription‑only bisphosphonate indicated for the treatment of osteoporosis in postmenopausal women and for preventing skeletal‑related events such as pathological fractures in patients with bone metastases.

Ibandronic Acid binds to bone mineral surfaces and, when osteoclasts attach, it is taken up into the cells where it blocks farnesyl pyrophosphate synthase in the mevalonate pathway. This inhibition leads to osteoclast apoptosis, reducing bone resorption and helping maintain bone strength.

The dosing regimen for Ibandronate Eg is determined by the prescribing clinician based on the patient’s condition, renal function, and treatment goals. Only a qualified healthcare professional should set the dose and administration schedule.

Safety data for Ibandronate Eg in pregnancy and lactation are limited. It is generally contraindicated unless the potential benefit justifies the potential risk to the fetus or infant, and it should only be used under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Ibandronate is similar to other bisphosphonates such as alendronate and zoledronic acid in its antiresorptive mechanism, but it is administered intravenously and has a longer dosing interval, which can improve patient convenience compared with more frequent oral regimens.

Ibandronate Eg should be stored at ambient temperature, below 25 °C, protected from light and moisture, and kept in its original packaging until ready for use. Do not freeze the solution.

The product is supplied as an intravenous solution that is administered by a qualified healthcare professional through a controlled IV infusion. The infusion rate and duration are determined by the prescriber and nursing staff according to clinical guidelines.

Serious risks include osteonecrosis of the jaw, atypical femoral fractures, and severe renal impairment. Patients should be monitored for signs of jaw pain, unusual thigh or groin pain, and changes in kidney function during treatment.

Ibandronate Eg is contraindicated in patients with severe renal impairment (eGFR <30 mL/min), known hypersensitivity to ibandronate or any formulation components, and in individuals with active dental infections or recent invasive dental procedures unless the benefits outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 31 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.